$3.06
▼ $-0.09
(-2.86%)
Vol 4.7M
5
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$524.8M
ROE
-60.2%
Margin
-4071.2%
D/E
0.65
Beta
2.15
52W
$2–$6
Wall Street Consensus
15 analysts · Apr 20263
Strong Buy
10
Buy
2
Hold
0
Sell
0
Strong Sell
86.7%
Buy Rating
Price Chart
Similar Stocks
Earnings
Beat rate: 40.0%
Next Report
May 11, 2026
EPS Estimate: $-0.20
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.20 | — | — |
| Dec 2025 | $-0.20 | $-0.20 | $0.00 |
| Sep 2025 | $-0.22 | $-0.20 | +$0.02 |
| Jun 2025 | $-0.22 | $-0.24 | $-0.02 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… |
|---|---|---|---|---|---|
| Revenue | $1.7M | $665K | $1.2M | $593K | $378K |
| Net Income | -$27.4M | -$29.0M | -$26.3M | -$30.6M | -$28.7M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -60.2% | -60.2% | -60.2% | -60.2% | -60.2% | -60.2% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -5155.0% | -2737.9% | -2737.9% | -2737.9% | -4071.2% | -4071.2% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 1.24 | 1.24 | 1.24 | 1.24 | 0.65 | 0.65 |
| Current Ratio | 4.39 | 4.39 | 4.39 | 4.39 | 5.89 | 5.89 |
Key Ratios
ROA (TTM)
-50.9%
P/S (TTM)
186.43
P/B
1.7
EPS (TTM)
$-0.90
CF/Share
$-1.01
Rev Growth 3Y
-1.8%
52W High
$6.33
52W Low
$2.01
$2.01
52-Week Range
$6.33
Financial Health
Free Cash Flow
-$26.0M
Net Debt
-$3.3M
Cash
$9.5M
Total Debt
$6.2M
As of Sep 30, 2025
How does ABSI compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
ABSI valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
186.4
▲
1351%
above
peers
(12.9)
vs Peers
vs Industry
Pricier
P/B ratio
1.7
▼
32%
below
peers
(2.5)
vs Peers
vs Industry
Pricier
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
ABSI profitability vs Biotechnology peers
ROE
-60.2%
▲
11%
above
peers
(-67.3%)
vs Peers
vs Industry
In line
Net margin
-4071.2%
▼
1320%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-50.9%
▼
9%
below
peers
(-46.7%)
vs Peers
vs Industry
In line
ABSI financial health vs Biotechnology peers
D/E ratio
0.7
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
In line
Current ratio
5.9
▲
33%
above
peers
(4.4)
vs Peers
vs Industry
Below avg
Beta
2.2
▲
122%
above
peers
(1.0)
vs Peers
vs Industry
More volatile
ABSI fundamentals radar
ABSI
Peer median
Industry
ABSI profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
ABSI vs peers: key metrics
Insider Activity
NeutralBuys
0
Sells
0
BUSCH ANDREAS
Officer · Mar 12
100000 shs
MCCLAIN SEAN
Chief Executive Officer · Mar 02
406200 shs
MCCLAIN SEAN
Chief Executive Officer · Mar 02
406200 shs
BEDRICK TODD
Officer · Mar 02
49600 shs
BEDRICK TODD
Officer · Mar 02
49600 shs
JONASSON ZACHARIAH
Chief Financial Officer · Mar 02
135400 shs
JONASSON ZACHARIAH
Chairman of the Board · Mar 02
135400 shs
WALKER SHELBY J
Officer · Mar 02
90300 shs
WALKER SHELBY J
Officer · Mar 02
90300 shs
PANGALOS MENELAS N
Director · Mar 02
5800 shs
Last 90 days
Top Holders
Top 5: 41.52%FMR, LLC
14.88%
$62.2M
ARK Investment Management, …
8.35%
$34.9M
Blackrock Inc.
7.54%
$31.5M
Redmile Group, LLC
5.49%
$22.9M
Vanguard Group Inc
5.26%
$22.0M
As of Dec 31, 2025
Latest News
No related news yet